Breaking News Instant updates and real-time market news.

AFL

Aflac

$88.95

-2.74 (-2.99%)

09:53
01/12/18
01/12
09:53
01/12/18
09:53

Aflac drops 4% after Intercept reports on fraud allegations by employees

AFL Aflac
$88.95

-2.74 (-2.99%)

09/26/17
SBSH
09/26/17
DOWNGRADE
Target $79
SBSH
Sell
Aflac downgraded to Sell from Neutral at Citi
Citi analyst Suneet Kamath downgraded Aflac to Sell and cut his price target for the shares to $77 from $82. The company is at an inflection point as Aflac Japan is too large to show meaningful growth and Aflac U.S. is "too small to move the growth needle," Kamath tells investors in a research note titled "Growth is Hard to Find, Other than in AFL's Valuation Multiples." The analyst estimates the annual earnings growth going forward at 1% and 5%, respectively, which he says is well below peer levels and "at odds" with the stock's valuation.
09/26/17
09/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) and PNC Financial (PNC) were downgraded to Hold from Buy at Deutsche Bank. 2. Aflac (AFL) downgraded to Sell from Neutral at Citi with analyst Suneet Kamath saying the company is at an inflection point as Aflac Japan is too large to show meaningful growth and Aflac U.S. is "too small to move the growth needle." 3. Cardtronics (CATM) downgraded to Market Perform from Outperform at William Blair with analyst Robert Napoli citing the changes in the Australian market. 4. Cheesecake Factory (CAKE), Shake Shack (SHAK), and Habit Restaurants (HABT) were downgraded to Neutral from Outperform at Wedbush. 5. Genocea (GNCA) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying his visibility and confidence "remains admittedly low" after the company shelved GEN-003 and said it will shift focus on immuno-oncology and the development of neoantigen cancer vaccines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/17
GSCO
10/18/17
INITIATION
Target $88
GSCO
Neutral
Aflac initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Alex Scott started Aflac with a Neutral rating and $88 price target while initiating coverage of the life insurance industry with a Neutral coverage view.
01/09/18
WELS
01/09/18
NO CHANGE
Target $90
WELS
Market Perform
Aflac price target raised to $90 from $84 at Wells Fargo
Wells Fargo analyst Sean Dargan raised his price target for Aflac to $90 from $84 after adjusting his Q4 2017, 2018 and 2019 EPS estimates. The analyst reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.